ArticleJournal of cancer research and clinical oncology2023
m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Heparin inhibits NLRP3-dependent pyroptosis in acute pancreatitis.Genes and immunity · 2026Article
- RBM15-Mediated m6A Modification Regulates Proliferation and Migration of Pancreatic Cancer Cells via the lncRNA LINC01320/miR-1287-5p/FBXO11 Axis.Biomolecules & therapeutics · 2026Article
- METTL16 in cancer: Roles and regulatory mechanisms.Genes & diseases · 2026Review
- METTL16 promotes PD-L1 expression and mediates immunosuppression in B-cell lymphomas via mAmerican journal of translational research · 2026Article
- Role of m6A RNA methylation regulators in pancreatic cancer: interactions and potential implications.Cancer cell international · 2025Review
- Role of the mInternational journal of molecular medicine · 2025Review
- METTL14‑mediated RNA methylation in digestive system tumors.International journal of molecular medicine · 2023Review
- Roles of RNA Methylations in Cancer Progression, Autophagy, and Anticancer Drug Resistance.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN6 methyladenosine (m6A) RNA methylation regulators play a key role in the occurrence and development of many tumors. However, the function of N6 methyladenosine (m6A) RNA methylation regulators in pancreatic adenocarcinoma (PAAD) has not been fully clarified.
methodsWe used data set from GEPIA 2, UALCAN, TIMER, TISIDB, CBioPortal database to analyze the gene expression of 20 major m6A RNA methylation regulators.
resultsOur study revealed that the irregularity of m6A regulators were associated with poor prognosis in PAAD. Meantime, 13 m6A regulators showed high expression in PAAD samples (ALKBH5, ELAVL1, FTO, HNRNPC, IGF2BP2, METTL14, METTL16 (METT10D), RBM15, VIRMA (KIAA1429), YTHDF1, YTHDF2, YTHDF3 and ZC3H13). In these regulators, we evaluated HNRNPC and IGF2BP2 were significantly correlated with worse outcomes and ALKBH5, IGF2BP2, METTL16 (METT10D), RBM15 were significantly correlated with PAAD in advanced stage. Moreover, we showed m6A regulators is correlated with Immuno-regulators' (Immunoinhibitors, Immunostimulators and MHC molecules) expression and levels of immune infiltration in PAAD. Bioinformatics further demonstrate m6A regulators were participated in revising in RNA processing.
conclusionsOur study investigated that the m6A regulatory factors may serve as a biomarker and a potential target of immunotherapy for PAAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.